Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Core Insights - Moleculin Biotech, Inc. announced the release of a webcast discussing final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin for treating soft tissue sarcoma lung metastases [2] - The company is advancing a pipeline of therapeutic candidates targeting hard-to-treat tumors and viruses, with Annamycin being a key program [5] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on drug candidates for difficult-to-treat cancers and viruses [2][5] - Annamycin is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with current treatments [5] - The company has initiated the MIRACLE Trial (MB-108), a Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia [6] Clinical Development - The Phase 1B/2 study (MB-106) of Annamycin has received positive input from the FDA, which the company believes has de-risked its development pathway for potential approval [6] - Moleculin is also developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122 for treating pathogenic viruses [7]